Report #2841404

Received May 16, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 74 yrs
State: FL
Recovered: Unknown
Vaccinated: May 7, 2025
Onset: May 7, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	TS525	SC

Symptoms (1)

Incorrect route of product administration

Symptom narrative

Shingrix - Subcutaneous injection; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 74-year-old male patient who received Herpes zoster (Shingrix) (batch number TS525, expiry date 10-MAR-2027) for prophylaxis. On 07-MAY-2025, the patient received Shingrix (subcutaneous). On 07-MAY-2025, an unknown time after receiving Shingrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Shingrix - Subcutaneous injection). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK receipt date: 07-MAY-2025 A pharmacist reported the administration of Shingrix via subcutaneous injection instead of intramuscular injection, which led to intramuscular formulation administered by other route. The pharmacist asked if the dose should be repeated.